It’s exciting to be the first and currently only lab to qualify the entire 54 V-PLEX offered by MSD. Clients developing small or large molecule therapeutics- or both, along with ADCs – are interested in biomarkers.
KANSAS CITY, Kan. (PRWEB) December 08, 2017
Following the company’s previous announcement of several key developments, including a multi-million dollar renovation and expansion of lab spaces, KCAS Bioanalytical and Biomarker Services announces the launch of the qualified Meso Scale Discovery’s (MSD) V-PLEX™ 54-plex biomarker panel, making it the first CRO to offer the qualified panel to customers.
The 54 separate analytes are associated with a wide number of diseases, such as autoimmune conditions, cancer, intestinal inflammation, obesity, heart disease, asthma, cardiovascular disease, bacterial infections, and fungal infections. The markers measured are human cytokines and chemokines related to a variety of biological mechanisms including inflammation, angiogenesis, chemotaxis, and Immune regulation.
KCAS, a CRO specializing in bioanalysis of large and small molecule therapeutics, can customize the markers in single-plex or multi-plex formats, based on client needs. The V-PLEX kits are provided in seven multiplex panels— Proinflammatory Panel 1, Cytokine Panel 1, Chemokine Panel 1, Angiogenesis Panel 1, TH17 Panel 1, Cytokine Panel 2, and Vascular Injury Panel 2. The panels are optimized to achieve the highest level of performance from each assay, providing efficient biomarker screening and profiling without compromising performance. The 54-plex panel can be initially used as a screening panel to identify relevant biomarkers, then be assembled into a custom panel for long-term studies. KCAS has initially qualified the panels in K2EDTA plasma and qualification in serum is underway.
Dr. Dominic Warrino, KCAS Senior Scientific Advisor, notes, “It’s exciting to be the first and currently only lab to qualify the entire 54 V-PLEX offered by MSD. Clients developing small or large molecule therapeutics – or both, along with ADCs are interested in biomarkers. The flexibility of the 54-plex allows individuals to select the analytes they need up to and including the entire panel. The 54-plex consists of 7 clinically validated panels that help scientists choose which analytes are a fit to understand the disease they are trying to treat or cure and the effect of the investigational new drug on the patient.”
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 38+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 10 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com